glp-1 and eating disorder Neurobiological Mechanisms Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Disorder: A Narrative Review GLP-1 and Eating Disorders: Risks

Such unwanted side effects include undesired tachycardia, increased lactic acidosis, cardiac arrhythmias (including atrial fibrillation) as well as the development of refractory shock (DeBacker et al, 2010

People who are obese or overweight tend to be good candidates here

Some protocols run 50100 mcg but the risk/benefit ratio shifts considerably above 50 mcg without meaningful additional evidence of proportional benefit

We also consider the effect of these molecules on other obesity-related complications [glycaemia in people with T2D and on liver fat content in people with MASLD/metabolic dysfunction-associated steatohepatitis (MASH, previously known as non-alcoholic steatohepatitis)] and we discuss the potential clinical implications and challenges that the new era in obesity pharmacotherapy will bring